WO2006026536A3 - Method of treatment of cancer using guanosine 3’, 5’ cyclic monophosphate (cyclic gmp) - Google Patents

Method of treatment of cancer using guanosine 3’, 5’ cyclic monophosphate (cyclic gmp) Download PDF

Info

Publication number
WO2006026536A3
WO2006026536A3 PCT/US2005/030626 US2005030626W WO2006026536A3 WO 2006026536 A3 WO2006026536 A3 WO 2006026536A3 US 2005030626 W US2005030626 W US 2005030626W WO 2006026536 A3 WO2006026536 A3 WO 2006026536A3
Authority
WO
WIPO (PCT)
Prior art keywords
cyclic
cyclic gmp
guanosine
cancer
decreases
Prior art date
Application number
PCT/US2005/030626
Other languages
French (fr)
Other versions
WO2006026536A2 (en
Inventor
David L Vesely
Original Assignee
Univ South Florida
David L Vesely
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Florida, David L Vesely filed Critical Univ South Florida
Priority to CA002579776A priority Critical patent/CA2579776A1/en
Publication of WO2006026536A2 publication Critical patent/WO2006026536A2/en
Publication of WO2006026536A3 publication Critical patent/WO2006026536A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid

Abstract

A method of treating cancer through use of guanosine 3',5'-cyclic monophosphate (cyclic GMP). Cyclic GMP decreases the number of human breast cancer and prostate adenocarcinoma as well as small-cell and squamous lung cells in culture by 30% (1 µM), 84% (1 mM), 31% (l µM), and 30% (1 µM), respectively. Cyclic GMP decreases DNA synthesis in human pancreatic, breast, and prostate adenocarcinomas as well as small-cell and squamous cell carcinomas of the lung at its 1 µM concentration by 51%, 54%, 56%, 50% and 52%, respectively. Cyclic GMP when infused for one week decreases the tumor volume of human pancreatic adenocarcinomas in athymic mice 95% compared to untreated animals with human pancreatic adenocarcinomas.
PCT/US2005/030626 2004-08-26 2005-08-26 Method of treatment of cancer using guanosine 3’, 5’ cyclic monophosphate (cyclic gmp) WO2006026536A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002579776A CA2579776A1 (en) 2004-08-26 2005-08-26 Method of treatment of cancer using guanosine 3', 5' cyclic monophosphate (cyclic gmp)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52217804P 2004-08-26 2004-08-26
US60/522,178 2004-08-26

Publications (2)

Publication Number Publication Date
WO2006026536A2 WO2006026536A2 (en) 2006-03-09
WO2006026536A3 true WO2006026536A3 (en) 2006-07-06

Family

ID=36000656

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/030626 WO2006026536A2 (en) 2004-08-26 2005-08-26 Method of treatment of cancer using guanosine 3’, 5’ cyclic monophosphate (cyclic gmp)

Country Status (2)

Country Link
CA (1) CA2579776A1 (en)
WO (1) WO2006026536A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488713B2 (en) 2004-03-18 2009-02-10 University Of South Florida Cancer treatment using C-type natriuretic peptides
WO2005094420A2 (en) 2004-02-17 2005-10-13 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
US7825092B2 (en) 2006-08-08 2010-11-02 University Of South Florida Dendroaspis natriuretic peptide for treatment of cancer
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] TURNER ET AL.: "Uridine cyclic nucleotide concentrations in cancer and other conditions; cyclic GMP: a potential marker for cancer treatment", accession no. STN Database accession no. (82266426) *
DATABASE MEDLINE [online] VESELY ET AL.: "Four peptides decrease the number of human pancreatic adenocarcinoma cells", accession no. STN Database accession no. (2003557220) *
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, vol. 33, no. 11, November 2003 (2003-11-01), pages 998 - 1005 *
JOURNAL OF CLINICAL PATHOLOGY, vol. 35, no. 8, August 1982 (1982-08-01), pages 800 - 806 *

Also Published As

Publication number Publication date
CA2579776A1 (en) 2006-03-09
WO2006026536A2 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
EP1242060A4 (en) Treatment of metastatic disease
NZ594950A (en) Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3
NZ626867A (en) Compositions and methods for the treatment of infections and tumors
WO2006052900A3 (en) Targeted innate immunity
EP1860119A4 (en) ANTI-IgSF4 ANTIBODY AND UTILIZATION OF THE SAME
WO2006060709A3 (en) Biological pathways in progenitor cells
WO2006026536A3 (en) Method of treatment of cancer using guanosine 3’, 5’ cyclic monophosphate (cyclic gmp)
WO2006004716A3 (en) Amelioration of drug-induced toxicity
SG171674A1 (en) Methods of treating cancer by administering human il-18 combinations
WO2004009112A8 (en) Use of urease for inhibiting cancer cell growth
WO2005041860A3 (en) Stem cells for use in locating and targeting tumor cells
WO2005094282A3 (en) Combination therapy comprising cloretazinetm
WO2006069217A3 (en) Small molecule cyclin d1 ablative agents
ATE394425T1 (en) METHOD FOR PRODUCING CYTOTOXIC ANTIBODIES AGAINST CANCER
CA2656005A1 (en) Chemotherapeutic compounds for selectively targeting tumor cells with fr type receptors
WO2005013802A3 (en) Trefoil factor 3 (tff3) as a target for anti-cancer therapy
DK1967586T3 (en) 84P2A9: prostate- and testicle-specific protein with high expression in prostate cancer
WO2005072292A3 (en) Methods for enhancing radiation therapy
WO2008063837A3 (en) Dendritic cell tumor injection therapy and related vaccine
Seemayer Methylation of DNA in vivo by thymus, spleen, and liver of the rat
WO2004034965A3 (en) Method for treating cancer
CN104224865B (en) Copper bores the test of the separation and Extraction and its anti-inflammatory activity of anti-inflammatory component
Hecht Carbohydrate-Targeted Antitumor Agents (for therapeutics)
Khallouf Immunochemotheraphy with 5-Fluorouracil and Interferon-alpha enhances the immunogenicity of murine pancreatic tumor via upregulation of a NKG2D ligands and MHC Class-I
Gopal et al. I-131-Anti-CD45 Radioimmunotherapy Effectively Targets and Treats T-Cell Non-Hodgkin's Lymphoma

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2579776

Country of ref document: CA

122 Ep: pct application non-entry in european phase